Genetic Transfer May Help Treat Impotence
In the first human trial to investigate gene transfer as a treatment for impotence, also referred to as erectile dysfunction, the approach appeared to be safe and provided some evidence that it is effective.
Scientists Create Artificial Penis
In the study, adult male rabbits with severely damaged penises received a graft of specially engineered penile tissue. The animals then re-grew full penises that functioned normally — even to the point of successfully impregnating females.
A Simple Injection Of Stem Cells From A Woman’s Own Muscle May Effectively Treat Urinary Incontinence
In the first clinical study of its kind in North America, women with stress urinary incontinence (SUI) were treated using muscle-derived stem cell injections to strengthen deficient sphincter muscles responsible for the condition.
Research in Stem Cells Produces Promising Results for Lupus Sufferers
In what is being called a huge development, researchers have found stem cells can wipe out lupus in certain patients.
University of Florida Scientists Restore Sight to Chickens with Blinding Disease
University of Florida scientists have delivered a gene through an eggshell to give sight to a type of chicken normally born blind.
Repairing the Heart with Cell Therapy and Nanofibers
The new system allows greater control of the intramyocardial environment by delivering growth factors to an injured heart muscle and using peptide nanofibers for prolonged delivery of the injected factor.
Published Independent Study Confirms Superiority of BioLife’s Products in Preserving Cord Blood Derived Stem Cells
BioLife Solutions, Inc., a leading manufacturer and marketer of cryopreservation solutions for the preservation of cells and tissues at low temperatures, announced today that an independent study published in the peer review journal Cytotherapy found BioLife’s CryoStor(TM) family of products to be significantly superior compared to traditional cord blood preservation methodologies.
HepaLife Technologies Inc.’s Liver Cell Function Plays Vital Role In Toxic, Brain Damaging Disease; National Institutes of Health (NIH) Launchs $71 Million Research Initiative
“HepaLife’s PICM-19 cell line is the only known, embryonic liver stem cell line of its kind with the ability to produce substantial amounts of urea, in an in vitro system,” explained Mr. Harmel S. Rayat, President and CEO of HepaLife.
Cancer Vaccine Shows Promise in Mice
The vaccine works by mimicking the effects of angiostatin, a piece of a protein that suppresses tumor growth by preventing new blood vessels from forming in tumors. This is a treatment strategy known as antiangiogenesis.
Cell Genesys Reports Interim Results of CG0070 Phase 1 Trial in Bladder Cancer
Cell Genesys, Inc. today announced preliminary results of a Phase 1 clinical trial of CG0070 in patients with recurrent bladder cancer who have failed previous therapy with bacillus Calmette-Guerin (BCG), the current standard therapy for recurrent bladder cancer.
Northwest Biotherapeutics Updates Brain Cancer Clinical Data
Northwest Biotherapeutics has released encouraging updated phase I survival and progression data on patients who have received DCVax-Brain, a therapeutic personalized cancer vaccine.
Long-Term Results from TNFerade(TM) Pancreatic Cancer Study and Updated Survival Results from TNFerade(TM) Esophageal Cancer Study Both Reported at Digestive Disease Week
GenVec, Inc. announced today that Kenneth Chang, M.D., medical director of the Comprehensive Digestive Disease Center at the University of California at Irvine and a clinical investigator for several studies involving GenVec’s investigational cancer drug TNFerade(TM), presented updated survival information from a clinical study demonstrating the potential utility of TNFerade in treating patients with esophageal cancer.
Positive Results for Prima BioMed’s Ongoing Phase IIa Ovarian Cancer Trial
A second analysis of data made available to Prima’s Scientific Advisory Panel (SAP) indicated that so far 21 per cent of patients in the trial had achieved either a clinical response to treatment or stabilisation of their disease.
Oxford BioMedica PLC Commences Phase II Trial Of Trovax(R) In Prostate Cancer
Oxford BioMedic, a leading gene therapy company, announced that a Phase II trial of TroVax in patients with prostate cancer that is unresponsive to hormone therapy is open for recruitment.
GVAX(R) Improves Survival in Metastatic Hormone-Refractory Prostate Cancer
Researchers have reported that the investigative immunotherapy agent GVAX improves predicted survival time with little toxicity in patients with metastatic hormone-refractory prostate cancer (HRPC).
Cell Analysis System Gleaned from Earth Sciences Technique
By combining multispectral analysis with flow cytometry, researchers can study a single cell in 32 colors. Such a complete spectral signature could help them better diagnose disease.
ABSTRACTS, REVIEWS & SPECIAL REPORTS
Isolation of a Novel Population of Multipotent Adult Stem Cells from Human Hair Follicles
The researchers isolated a novel population of multipotent adult stem cells from human hair follicles, and these cells appear to be located in the bulge area.
Current Prospects for Adult Stem Cell–Based Therapies in Ocular Repair and Regeneration
Here the researchers discuss the current prospects for the application of various adult ocular stem cells to human therapies for restoration of vision.